Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
Pheast Therapeutics
Centre Leon Berard
Washington University School of Medicine
Memorial Sloan Kettering Cancer Center
Massachusetts General Hospital
Telix Pharmaceuticals (Innovations) Pty Limited
M.D. Anderson Cancer Center
Seattle Children's Hospital
Nationwide Children's Hospital
The New York Proton Center
Hoffmann-La Roche
Stemline Therapeutics, Inc.
Eastern Cooperative Oncology Group
National Institutes of Health Clinical Center (CC)
University of California, San Francisco
Baptist Health South Florida
Neonc Technologies, Inc.
OHSU Knight Cancer Institute
Memorial Sloan Kettering Cancer Center
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Columbia University
Australian & New Zealand Children's Haematology/Oncology Group
St. Jude Children's Research Hospital
Jazz Pharmaceuticals
ITM Solucin GmbH
Weill Medical College of Cornell University
Cedars-Sinai Medical Center
Plus Therapeutics
Binhui Biopharmaceutical Co., Ltd.
Barbara Ann Karmanos Cancer Institute
Miltenyi Biomedicine GmbH
Rigshospitalet, Denmark
University Hospital Heidelberg